FierceBiotech names Navitor Pharmaceuticals as one of its "Fierce 15" Biotech Companies of 2014

Cambridge, MA – September 22, 2014 – Navitor Pharmaceuticals, Inc., today announced 
that it has been named by FierceBiotech as one of 2014's Fierce 15 biotechnology 
companies, designating it as one of the most promising private biotechnology companies 
in the industry. Navitor is developing novel medicines through targeting cellular nutrient 
signaling by selectively modulating mTORC1, a fundamental and clinically-validated 
pathway which regulates cell growth and function. 
"Navitor has zeroed in on a very specific biological pathway with some impressively 
broad applications, and the company's technology has the potential to generate novel 
treatments for a few of the world's most widespread diseases," says Damian Garde, editor 
of FierceBiotech. "That promise was enough to convince some A-list investors, and Navitor 
is well on its way to addressing some ambitious goals."
Navitor's proprietary drug discovery platform is designed to develop first-in-class 
selective modulators of mTORC1 to address a wide range of diseases, including metabolic, 
neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare 
disorders. The company has exclusive access from the Whitehead Institute to fundamental 
intellectual property relating to nutrient sensing via the mTORC1 pathway from the 
laboratory of David M. Sabatini, MD, PhD, Professor of Biology at MIT, Member of the 
Whitehead Institute for Biomedical Research, and Investigator at the Howard Hughes 
Medical Institute. Dr. Sabatini, Navitor's scientific founder, has led groundbreaking 
research in the molecular regulation of the mTORC1 pathway, and his discoveries are 
seminal contributions to the field of cellular nutrient signaling. 
"We are honored to be recognized as one of the innovative companies selected for this 
year's FierceBiotech 'Fierce 15'," said George P. Vlasuk, PhD, President and Chief Executive 
Officer of Navitor. "We are harnessing newly discovered nutrient signaling mechanisms 
of mTORC1 that drive protein synthesis and cellular growth to allow the development of 
novel medicines for a wide range of chronic diseases and rare disorders. The prospect of 
developing innovative medicines that can significantly impact the lives of patients truly 
motivates our experienced team and world-class scientific advisory board, and we look 
forward to building our company around Navitor's proprietary technology platform."
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and 
creativity, even in the face of intense competition. This is FierceBiotech's twelfth annual 
Fierce 15 selection. A complete list of "Fierce 15" companies can be found online at 
Every year FierceBiotech evaluates hundreds of private companies from around the world 
for its annual Fierce 15 list, which is based on a variety of factors such as the strength 
of its technology, partnerships, venture backers and a competitive market position. An 
internationally recognized daily report reaching a network of over 270,000 biotech and 
pharma industry professionals, FierceBiotech provides subscribers with an authoritative 
analysis of the day's top stories.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource 
providing the latest biotech news, articles, and resources related to clinical trials, drug 
discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company 
news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an 
insider briefing on the day's top stories. Signup is free at 
About Navitor Pharmaceuticals
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines 
by targeting cellular nutrient signaling pathways. The company's proprietary drug 
discovery platform targets mTORC1, which responds to and integrates the cell's response 
to nutrient availability and plays a key role in protein synthesis and cellular growth. 
Navitor's therapeutics are designed to selectively modulate the cellular signals that 
are aberrant in disease processes caused by the dysregulation of mTORC1 activity to 
address a wide range of diseases, including metabolic, neurodegenerative, autoimmune 
and musculoskeletal diseases, as well as several rare disorders. The company's founding 
intellectual property is based on the groundbreaking discoveries related to the mTORC1 
pathway and nutrient signaling mechanisms by Dr. David Sabatini at The Whitehead 
Institute for Biomedical Research. The company is backed by leading financial and 
corporate investors, including Polaris Partners, Atlas Venture, Johnson & Johnson 
Development Corporation, SR One and The Longevity Fund. For more information, please 
Rebecca Friend
For Navitor:
Kathryn Morris
The Yates Network

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.